Axsome Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Feb 23, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 23, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on this 23rd day of February 2026.
| AXSOME THERAPEUTICS, INC. | |
| By | /s/ Herriot Tabuteau, M.D. |
| Herriot Tabuteau, M.D. | |
| Chief Executive Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated:
| Signature | Title | Date |
|---|---|---|
| /s/ Herriot Tabuteau, M.D.Herriot Tabuteau, M.D. | Chief Executive Officer and Chairman of the Board (Principal Executive Officer) | February 23, 2026 |
| /s/ Nick PizzieNick Pizzie | Chief Financial Officer(Principal Financial and Accounting Officer) | February 23, 2026 |
| /s/ Roger Jeffs, Ph.D.Roger Jeffs, Ph.D. | Director | February 23, 2026 |
| /s/ Mark Coleman, M.D.Mark Coleman, M.D. | Director | February 23, 2026 |
| /s/ Mark SaadMark Saad | Director | February 23, 2026 |
| /s/ Susan Mahony, Ph.D., M.B.A.Susan Mahony, Ph.D., M.B.A. | Director | February 23, 2026 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.